scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.RADONC.2016.08.015 |
P698 | PubMed publication ID | 27600155 |
P50 | author | Erik Holmberg | Q41783678 |
P2093 | author name string | Rolf Lewensohn | |
Jan Nyman | |||
Ingmar Lax | |||
Signe Friesland | |||
Bengt Bergman | |||
Per Bergström | |||
Andreas Hallqvist | |||
Jo-Åsmund Lund | |||
Odd-Terje Brustugun | |||
P433 | issue | 1 | |
P921 | main subject | adaptive radiation therapy | Q180507 |
P304 | page(s) | 1-8 | |
P577 | publication date | 2016-09-03 | |
P1433 | published in | Radiotherapy and Oncology | Q14251029 |
P1476 | title | SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. | |
P478 | volume | 121 |
Q90296646 | A Population-based Study of the Effectiveness of Stereotactic Ablative Radiotherapy Versus Conventional Fractionated Radiotherapy for Clinical Stage I Non-small Cell Lung Cancer Patients |
Q90415320 | A Prediction Model to Help with Oncologic Mediastinal Evaluation for Radiation: HOMER |
Q48312990 | A dosimetric parameter to limit chest wall toxicity in SABR of NSCLC. |
Q59799824 | A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer |
Q38790915 | A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer |
Q64325572 | Advances in proton therapy in lung cancer |
Q91632005 | CHISELing a path forward in the treatment of early-stage non-small-cell lung cancer |
Q88813122 | Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years |
Q99240991 | Chest wall toxicity after stereotactic radiation in early lung cancer: a systematic review |
Q57279966 | Clinical trials involving carbon-ion radiation therapy and the path forward |
Q58804834 | Combining immunotherapy with radiation therapy in thoracic oncology |
Q47446694 | Comparison of Single- and Three-fraction Schedules of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-Small-cell Lung Cancer. |
Q43191730 | Cons: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy? |
Q89869712 | Contrast enhanced oesophageal avoidance for stereotactic body radiotherapy: Barium vs. Gastrografin |
Q60908706 | Developments in Stereotactic Body Radiotherapy |
Q36729311 | Disparities in treatment of patients with inoperable stage I non-small cell lung cancer: a population-based analysis |
Q55001587 | Feasibility of stereotactic body radiotherapy for locally-advanced non-small cell lung cancer. |
Q89572724 | Feasibility of stereotactic radiotherapy for lung lesions and conventional radiotherapy for nodal areas in primary lung malignancies |
Q102067109 | Hypo-fractionation radiotherapy normalizes tumor vasculature in non-small cell lung cancer xenografts through the p-STAT3/HIF-1 alpha signaling pathway |
Q30238797 | Influence of dose and fractionation in radiation therapy of curative intent for non-small cell lung cancer |
Q48128980 | Managing an Older Adult with Cancer: Considerations for Radiation Oncologists |
Q61804649 | Medically inoperable stage I non-small cell lung cancer: best practices and long-term outcomes |
Q92461774 | Outcomes Following Stereotactic Body Radiotherapy with Intensity-Modulated Therapy versus Three-Dimensional Conformal Radiotherapy in Early Stage Non-Small Cell Lung Cancer |
Q35880933 | Outcomes after Stereotactic Body Radiotherapy versus Limited Resection in Older Patients with Early-Stage Lung Cancer. |
Q96305367 | Outpatient Anesthesia Facilitates Stereotactic Body Radiation Therapy for Early Stage Lung Cancer Patients With Advanced Cognitive Impairments |
Q64277127 | Phase II study of compensator-based non-coplanar intensity-modulated radiotherapy for Stage I non-small-cell lung cancer |
Q56528378 | Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie? |
Q94465235 | Pretreatment Factors Influencing Radiation Pneumonitis after Stereotactic Body Radiation Therapy in the Treatment of Lung Cancer |
Q91830232 | Prognostic Role Of Computed Tomography Textural Features In Early-Stage Non-Small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy |
Q89996520 | Prognostic impact of solid tumor component diameter in early-stage non-small cell lung carcinoma treated with intensity-modulated fractionated radiotherapy: a retrospective analysis impact of solid tumor component diameter in NSCLC treated with IMRT |
Q60938857 | Promising Clinical Outcome With Long Term Follow-Up After Body Gamma Knife Stereotactic Radiosurgery for Patients With Early Stage Non-small Cell Lung Cancer |
Q55038620 | Radiation Oncology in the 21st Century: Prospective Randomized Trials That Changed Practice… or Didn't! |
Q47718099 | Radiobiological Optimization in Lung Stereotactic Body Radiation Therapy: Are We Ready to Apply Radiobiological Models? |
Q42109226 | Radiotherapy for Oligometastatic Lung Cancer |
Q94592974 | Radiotherapy in Lung Cancer: Current and Future Role |
Q58804832 | Reirradiation for locoregionally recurrent non-small cell lung cancer |
Q47115640 | Research in imaging/biomarkers for precision medicine in lung cancer: National Cancer Institute funding opportunities |
Q64106509 | Research of Biological Dose Conversion Platform Based on a Modified Linear Quadratic Model |
Q48282380 | Rethink radiotherapy - BIGART 2017. |
Q48233447 | Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer. |
Q91684310 | SABR versus conventional fractionation regimens in NSCLC |
Q95473369 | SABR versus conventional fractionation regimens in NSCLC |
Q89932945 | Single-lung stereotactic body radiotherapy: A case report and discussion of therapeutic challenges |
Q53822924 | Standard of care in high-dose radiotherapy for localized non-small cell lung cancer. |
Q98289160 | Stereotactic ablative body radiotherapy versus conventionally fractionated radiotherapy for early stage large cell neuroendocrine carcinoma of the lung |
Q91631990 | Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial |
Q57172947 | Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances |
Q89005809 | Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC) |
Q55282076 | Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives. |
Q57177641 | Stereotactic body radiation therapy for lung, spine and oligometastatic disease: current evidence and future directions |
Q60912983 | Stereotactic body radiation therapy for non-small cell lung cancer: A review |
Q91875040 | Stereotactic body radiation therapy for oligometastatic pulmonary tumors from cervical cancer |
Q64096283 | Stereotactic body radiation therapy in early-stage NSCLC: historical review, contemporary evidence and future implications |
Q61804651 | Stereotactic body radiotherapy for centrally located stage I non-small cell lung cancer |
Q89870886 | Stereotactic body radiotherapy for elderly patients (≥ 75 years) with early-stage non-small cell lung cancer |
Q90591596 | Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer |
Q28085744 | Stereotactic radiotherapy for early lung cancer: Evidence-based approach and future directions |
Q35824255 | Stereotactic radiotherapy for early stage non-small cell lung cancer |
Q47275269 | Survival of localized NSCLC patients without active treatment or treated with SBRT. |
Q38962875 | Triaging early-stage lung cancer patients into non-surgical pathways: who, when, and what? |
Search more.